Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

作者：Louis J. Aronne, Naveed Sattar, Deborah B. Horn, Harold Bays, Sean Wharton, Wen‐Yuan Lin, Nadia N. Ahmad, Shuyu Zhang, Ran Liao, Mathijs C. Bunck, Irina Jouravskaya, Madhumita A. Murphy, SURMOUNT-4 Investigators, Jose Osvaldo Fretes, Maria Jimena Coronel, Lucas L Gutnisky, Gustavo Frechtel, Elizabeth Gelersztein, Diego Aizenberg, Natacha Maldonado, Márcio Pereira, Queulla G Santos, Camila Calil Salim, Luís Henrique Santos Canani, Bruno Halpern, Luis AT Russo, Joselita Bodart, Danilo V Neto, Gustavo Augusto, Silmara Leite, Yi‐Ching Yang, Wen-Yuan Lin, Chien‐Ning Huang, Kuo‐Chin Huang, David Fitz-Patrick, Cindy HT Pau, Phillip D. Toth, G.H. Freeman, Donald F Gardner, Alan Wynne, Juan Loy, Deborah B. Horn, Purvi Mehra, Stacey Layle, James H. Bergthold, José de Souza, Venkatesh Nadar, G Angulo, Ken Cohen, Timothy R. Smith, Louis J. Aronne, Michael G. Vaughn, Altagracia Aurora Alcantara-Gonzalez, Seth Forman, John Agaiby, S Geller, Neil J. Fraser, Robert A. Jenders, Kim Barbel-Johnson, Ronald K. Mayfield, Carl D Vance, Kevin T Prier, Alexander V. Murray, Michael Lillestol, Douglas Denham, Jean Park, E. Klein, Harold Bays, Athena Philis‐Tsimikas, Peter E Bressler, John C.H. Reed, Shamaila Aslam, Julio Rosenstock, Juan P. Frías, Leslie J. Klaff, Ronald Brazg, Martha Gomez-Cuellar, Lisa Connery, Joanna Van, Jean-Louis Sélam, John Kim, Dwight Blake, John Gabriel, Samir Arora, Michael J McCartney, Royce Keith Solano, Steven K Brodie, John Nardandrea · 发表于：JAMA · 年份：2023 · DOI：10.1001/jama.2023.24945 · 被引用次数：798 · 研究领域：Bariatric Surgery and Outcomes、Pharmacology and Obesity Treatment、Body Contouring and Surgery

Importance: The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective: To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. Design, Setting, and Participants: This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes. Interventions: Participants (n = 783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks. Main Outcomes and Measures: The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80% of the weight loss during the lead-in period. Results: Participants (n = 670; mean age, 48 years; 473 [71%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9%. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide v...